In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lonza Group Ltd.

www.lonza.com

Latest From Lonza Group Ltd.

COVID-19 Vaccine Manufacturing: Moderna CEO Worries Most About Raw Materials

Moderna's Bencal and Merck Vaccine head Markels discuss the difficulties in scaling up manufacturing capacity for vaccine candidates at BIO plenary session; CEPI CEO says his organization can help facilitate pairing of vaccine development partners.

Coronavirus COVID-19 Vaccines

Moderna Phase III COVID-19 Vaccine Plan To Enroll 30,000 Patients

The company finalized the Phase III program based on feedback from the US FDA and plans to start the study in July. With a 100 µg dose, Moderna says it can manufacture 500 million doses a year.

Coronavirus COVID-19 Vaccines

People On The Move: Appointments At RB, Ipsen, Lonza, Phoenix And Stada

Reckitt has a new chief supply officer, while Ipsen and Lonza have both appointed CEOs. Meanwhile, Phoenix and Stada have made leadership changes in Germany.

Appointments Leadership

Gamida Cell’s Bone Marrow Transplant Alternative Succeeds In Phase III

The Novartis-backed company will begin a rolling submission to the US FDA for its cord blood-derived cell therapy omidubicel in Q4 based on improved engraftment versus standard cord blood. 

Clinical Trials Regenerative Medicine
See All

Company Information

UsernamePublicRestriction

Register